Competition in US migraine prevention market

28 January 2019

The migraine market has seen a game-change with the approvals and launches of a new and much-anticipated class of therapy, calcitonin gene-related peptide (CGRP) inhibitors.

In the US migraine prevention market, Amgen (Nasdaq: AMGN) and Novartis’ (NOVN: VX) Aimovig (erenumab-aooe) is benefiting from its first-to-market position in the anti-calcitonin gene-related peptide (CGRP) class, which first saw the advent of competition following the September 2018 approvals of Teva Pharmaceutical Industries (NYSE: TEVA)’s Ajovy (fremanezumab) and Eli Lilly’s (NYSE: LLY) Emgality (galcanezumab.

In the current wave of the ongoing quarterly RealTime Dynamix™: Migraine Prevention (US) report series from Spherix Global Insight, almost all US neurologists and migraine/headache specialists (n=104) surveyed in late November/early December 2018 reported having initiated at least one patient on Aimovig. In comparison, only about half of physicians had clinical experience with Ajovy or Emgality two months after their respective launches, with Ajovy slightly outpacing Emgality.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK